Human papillomavirus-16 E6 variants in cervical squamous intraepithelial lesions from HIV-negative and HIV-positive women

American Journal of Clinical Pathology

Volumn 116, Issue 1, 2001, Pages 143-148

  Pérez Gallego, Lucía ^a   Moreno Bueno, Gema ^b   Sarrió, David ^b   Suárez, Asunción ^c   Gamallo, Carlos ^d   Palacios, José ^b,e  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

E6 prototype and variants; Human papillomavirus type 16; SIL; Squamous intraepithelial lesion

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; VIRUS TYPING; WART VIRUS;

ADOLESCENT; ADULT; BASE SEQUENCE; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; UTERINE CERVICAL DISEASES; VARIATION (GENETICS);

EID: 0034955154     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/42U5-Q2EV-RCBM-WPGJ     Document Type: Article

References (37)

1. Schiffman MH. New epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst. 1995; 87:132-134.
2. Chua KL, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer. 1996;77:121-127.
3. Ho GYF, Burk RD, Klein S, et al. Persistent genital human papillomavirus infections as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87:1365-1371.
4. Ho GYH, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;38:423-427.
5. Stoler MH. The biology of human papillomaviruses. Pathol Case Rev. 1997;2:8-20.
6. van Ranst MA, Tachezy R, Delius H, et al. Taxonomy of the human papillomaviruses. Papillomavirus Rep. 1993;4:61-65.
7. de Villiers EM. Human pathogenic papillomavirus types: an update. Curr Top Microbiol Immunol. 1994;186:1-12.
8. Stewart ACM, Erilsson AM, Manos MM, et al. Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol. 1996;70:3127-3136.
9. Ho L, Chan SY, Burk RD, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol. 1993;67:6413-6423.
10. Yamada T, Wheeler CM, Halpern AL, et al. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol. 1995;69:7743-7753.
11. Wheeler CM, Yamada T, Hildesheim A, et al. Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. J Clin Microbiol. 1997;35:11-19.
12. Yamada T, Manos MM, Peto J, et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol. 1997;71:2463-2472.
13. Xi LF, Demers GW, Koutsky LA, et al. Analysis of human papillomavirus type 16 variants indicate establishment of persistent infection. J Infect Dis. 1995;172:747-755.
14. Londesborough P, Ho L, Terry G, et al. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. Int J Cancer. 1996;69:364-368.
15. Xi LF, Koutsky LA, Galloway DA, et al. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst. 1997;89:796-802.
16. Xi LF, Critchlow CW, Wheeler CM, et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res. 1998;38:3839-3844.
17. Zehbe I, Wilander E, Delius H, et al. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Res. 1998;58:829-833.
18. Nindl I, Rindfleisch K, Lotz B, et al. Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. Int J Cancer. 1999;82:203-207.
19. Ting Y, Manos M. Detection and typing of genital human papillomaviruses. In: Innis MA, Gelfand DH, Sninsky JJ, et al, eds. PCR Protocols: A Guide to Methods and Applications. San Diego, CA: Academic Press; 1990:356-367.
20. Bosch FX, Manos MM, Muñoz N, et al, for the International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 1995;7:796-802.
21. Bergeron C, Barrasso R, Beaudenon S, et al. Human papillomaviruses associated with cervical intraepithelial neoplasia. Am J Surg Pathol. 1992;16:641-649.
22. Lungu O, Sun XW, Felix J, et al. Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia. JAMA. 1992;267:2493-2496.
23. Bauer HM, Ting Y, Greer C, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA. 1991;265:472-477.
24. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169:235-240.
25. Walling KL, Wilkund F, Angström T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999;341:1633-1638.
26. Hu X, Guo Z, Tianyun P, et al. HPV typing and HPV 16 E-6 sequence variation in synchronous lesions of cervical squamous-cell carcinoma from Swedish patients. Int J Cancer. 1999;83:34-37.
27. Zehbe I, Voglino G, Delius H, et al. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms [letter]. Lancet. 1998;352:1441-1442.
28. Nindl I, Rindfleisch K, Teller K, et al. Cervical cancer, HPV16 E6, variant genotypes, and serology [letter]. Lancet. 1998;353:153.
29. Stöppler MC, Ching K, Stöppler H, et al. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J Virol. 1996;70:6987-6993.
30. Kadish AS, Ho GYF, Burk RD, et al. Lymphoproliferative response to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J Natl Cancer Inst. 1997;89:1285-1293.
31. Nakagawa M, Stites DP, Farhat S, et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. J Infect Dis. 1997;175:927-931.
32. Peng S, Frazer IH, Fernando GJ, et al. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology. 1998;240:147-157.
33. Kast WM, Brandt RMP, Sidney J, et al. Role of HLA-motifs in the identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol. 1994;152:3904-3912.
34. Ellis JRM, Keating PJ, Baird J, et al. The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med. 1995;1:464-470.
35. Mainman M. Management of cervical neoplasia in human immunodeficiency virus-infected women. Monogr J Natl Cancer Inst. 1998;23:43-49.
36. Palefsky JM, Minkoff H, Kalish LA, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst. 1999;91:226-236.
37. Alemi M, Andersson S, Sällstrom J, et al. Rapid test for identification of a human papillomavirus 16 E6 variant. Diagn Mol Pathol. 1999;8:97-100.